Statistical innovations in the medical device world sparked by the FDA

被引:21
作者
Campbell, Gregory [1 ]
Yue, Lilly Q. [1 ]
机构
[1] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA
关键词
Adaptive designs; Bayesian statistics; clinical trials; diagnostic test evaluation; missing data; propensity score; quantitative benefit-risk; PROPENSITY SCORE; REGULATORY ISSUES; MISSING DATA; DESIGN; PREFERENCES; CHALLENGES; ACCURACY; RISKS;
D O I
10.1080/10543406.2015.1092037
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The world of medical devices while highly diverse is extremely innovative, and this facilitates the adoption of innovative statistical techniques. Statisticians in the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) have provided leadership in implementing statistical innovations. The innovations discussed include: the incorporation of Bayesian methods in clinical trials, adaptive designs, the use and development of propensity score methodology in the design and analysis of non-randomized observational studies, the use of tipping-point analysis for missing data, techniques for diagnostic test evaluation, bridging studies for companion diagnostic tests, quantitative benefit-risk decisions, and patient preference studies.
引用
收藏
页码:3 / 16
页数:14
相关论文
共 49 条
[1]  
[Anonymous], BEN RISK FACT CONS D
[2]  
[Anonymous], 2006, AD DES MED DEV CLIN
[3]  
[Anonymous], 2007, Statistical guidance on reporting results from studies evaluating diagnostic tests
[4]  
[Anonymous], GUID IND CLIN INV FO
[5]  
[Anonymous], PREV TREATM MISS DAT
[6]  
[Anonymous], STAT MED
[7]  
[Anonymous], ENCY BIOPHARMACEUTIC
[8]  
[Anonymous], STOCHASTIC MUSINGS P
[9]  
[Anonymous], 2011, STAT METHODS DIAGNOS, DOI DOI 10.1002/9780470906514
[10]  
[Anonymous], 2010, Guidance for Industry and FDA Staff - Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems